Zelira Therapeutics Ltd. announced that it has advised the following clarification in relation to the `Zelira Therapeutics Expands HOPETM Distribution to Washington DC, USA' dated 14 December 2020: Zelira does not consider the upfront fee to be material. The royalty of course has the potential to be material, but it is to be based on sales, and therefore the Company has no reasonable method of quantifying that amount. The contract can be terminated if net sales of the products for any four consecutive quarterly periods beginning with the fourth quarterly period after the effective date of first product sale are less than USD 250,000. Two years, automatically renewable yearly, at upon the mutual consent of both parties, for an additional three-year term. There are no conditions precedent that remain unsatisfied.